SCL Science's subsidiary SCL Healthcare announced on the 1st that it has secured strategic investment from JNPMEDI. This investment will be conducted in two phases as redeemable convertible preferred stock (RCPS) and will take place by early next year.
SCL Healthcare is set to embark on building a research infrastructure based on pharmacokinetic (PK) analysis in collaboration with JNPMEDI. Through this, the company plans to promote development of new healthcare services, enhancement of artificial intelligence (AI)-based platforms, and strengthening of precision data analysis technologies.
In particular, the company expects that once the pharmacokinetic analysis infrastructure is completed next year, it will be able to secure a competitive advantage in the analysis-oriented clinical research organization (CRO) market. With this investment, there will be an acceleration in strengthening partnerships in the CRO field and securing clients, leading to visible financial results.
A representative from SCL Healthcare noted, "A platform model that provides integrated precision diagnostics and clinical trial support based on PK analysis is rapidly spreading across the healthcare industry. We aim to establish a foundation to expand into high-value healthcare services such as precision medicine, digital therapeutics, and real-world evidence (RWE) based clinical research, based on the PK analysis infrastructure."